Did you miss the live webinar of our Capital Markets Day? You can watch 📽️ the full event recording, including presentations from our internal experts and industry leaders, a virtual tour and an overview of hVIVO's history of providing world leading human challenge trial services 🔬 Watch it here: https://lnkd.in/eDxZPxDJ #HVO #CMD
hVIVO
Biotechnology Research
London, England 11,073 followers
The world leader in testing infectious & respiratory disease products using human challenge trials. Ticker: HVO
About us
hVIVO plc (ticker: HVO) (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies. The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services. hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.
- Website
-
http://www.hvivo.com
External link for hVIVO
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- London, England
- Type
- Public Company
- Founded
- 1989
- Specialties
- clinical trials, uk clinical trials, clinical research, challenge models, human challenge models, human volunteer research, respiratory disease research, medical research, asthma studies, copd, influenza, human models of disease, clinical research, challenge studies, human challenge trials, RSV, malaria, HRV, Respiratory syncytial virus, Human rhinoviruse, lab services, and covid 19
Locations
-
Primary
Get directions
40 Bank Street
London, England E14 5NR, GB
-
Get directions
Fitzwilliam Hall, Fitzwilliam Place
4th Floor
Dublin, County Dublin D02, IE
Employees at hVIVO
Updates
-
Yesterday's H1 2024 Trading Update was covered in an interview with our CEO Yamin 'Mo' Khan and Vox Markets. 💥 Trading update highlights 🔬 State-of-the-art facility in Canary Wharf 👩🔬 Largest field study contract to date Tune in here: https://lnkd.in/d5q7b3MA #HVO #CanaryWharf
Q&A with hVIVO’s Mo Khan
https://www.youtube.com/
-
Our #CEO Yamin 'Mo' Khan discussed this mornings H1 2024 Trading Update with Proactive: 💪 Record revenue & EBITDA margin for H1 2024 📚 Overview of weighted contracted orderbook ✅ Reiterated 2024 guidance 🏙️ Canary Wharf facilities 🔬 Largest field study contract to date Watch the full interview here: https://lnkd.in/g86sdMnz #HVO #TradingUpdate #CanaryWharf
hVIVO achieves record first-half revenue as it expands with new Canary Whart headquarters
https://www.youtube.com/
-
A reminder 🔔 to register for today's live-stream event of our Capital Markets Day at 10am. ✅Trading Update 💡Deeper insight into the capabilities of the world's largest human challenge trial unit 💪 Enhancing & broadening of our services 🗣️ Speakers from hVIVO 🔑 Fireside chat with Key Opinion Leaders Register for the live-stream event here: https://lnkd.in/eDxZPxDJ #HVO
-
-
H1 2024 Trading Update: 📈H1 revenue growth of 30.6% to £35.6m 🟢EBITDA margin: c.24% 💰 Cash: £37.1m 📚Weighted contracted orderbook: £71m 🛌 Quarantine facility in Canary Wharf now fully operational providing the foundation and capacity for future growth ✅Full year revenue guidance reaffirmed & EBITDA anticipated to be at the upper end of market expectations Read the full announcement here: https://lnkd.in/eaMdgKdw #HVO #TradingUpdate
-
Last week we hosted the opening of the world's largest human challenge trial unit at Canary Wharf for our partners, clients, academics and industry colleagues. The event featured guided tours of our new state-of-the-art facility plus presentations from our hVIVO team and guest speakers including Bassam Hallis from the UK Health Security Agency, Peter Openshaw of Imperial College London & Stephen Lockhart. Thank you to everyone who attended, stay tuned for the full photo album and video of the event. #HVO #CanaryWharf #ScientificResearch #OpeningEvent
-
-
-
-
-
+5
-
-
We will be heading to Vienna to attend the European Respiratory Society ERS Congress, an annual event that brings together the world’s respiratory experts to showcase all the latest advances in respiratory medicine and science 🛫 Meet with our colleagues Ian Meikle and Alexander Mann to discuss hVIVO’s support of field-based airway disease trials, as well as our world leading reputation for testing vaccine and drug efficacy in human challenge trials. Learn more about our new 50 bed inpatient facility in Canary Wharf and 14 bed outpatient provision, with supporting laboratories, all of which can help further advance respiratory medicine research 🔬 Connect 🤝with the team at the event or reach out directly to schedule a meeting! Learn more: https://lnkd.in/dWng7gC #ERS2024 #HVO #Conference #RespiratoryDisease
-
A reminder that we will be hosting a Capital Markets Day on the 17th of July at 10am BST: ✅Trading Update 💡Deeper insight into the capabilities of the world's largest human challenge trial unit 💪 Enhancing & broadening of our services 🗣️ Speakers from hVIVO 🔑 Fireside chat with Key Opinion Leaders Register for the live-stream event here: https://lnkd.in/eDxZPxDJ #HVO #CanaryWharf #CapitalMarketsDay
-
Our CEO Yamin 'Mo' Khan spoke to the Canary Wharf Group on our world leading title, human challenge trials & the move to Canary Wharf. He highlights our new sate-of-the-art facility which is the world's largest human challenge trial unit, placed at the centre of a growing life science community at Canary Wharf. Tune in here: https://lnkd.in/eb9AwDR6 #HVO #CanaryWharf #NewFacility #LifeScience #CRO #HumanChallengeTrials #London #ScientificResearch
hVIVO Joining the Life Science Hub at Canary Wharf
https://www.youtube.com/
-
Our move to the worlds largest human challenge trial unit in Canary Wharf and our FluCamp volunteer recruitment platform was featured in Saturday's The Telegraph magazine: 🏙️"In terms of its scale, its the first of it's kind" 🔬Our leading Human Challenge Trials & their role in drug development 👨⚕️ Overview of FluCamp & the experience of our volunteers Read the full article here: https://lnkd.in/evszw5Cp #HVO #FluCamp #Telegraph #ScientificResearch